About
About

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
About Us

Leadership

Board of Directors

PCA Regenerative Medicine Advisory Board

Clinical Advisory Board
Our Science
Our Science

Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivate progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
PCA Approach

Therapeutic Discovery Process

Publications
Pipeline & Programs
Pipeline & Programs

Naturally repairing or reversing damage caused by degenerative disease
Pipeline

Hearing Program

Multiple Sclerosis Program

Strategic Partnerships
Hearing Loss
Hearing Loss

Hearing loss caused by damage to the sensory cells of the ear impacts hundreds of millions of people globally. Currently there are no FDA-approved treatments to address the underlying condition.
About Hearing Loss

How We Hear

Sensorineural Hearing Loss

Sound Clarity and Understanding Speech

Hearing Loss: A Growing Public Health Problem
Investors & Media
Investors & Media
Overview

Corporate Governance

Press Releases

Events & Presentations

Stock Information

Analyst Coverage

SEC Filings

Annual Reports and Proxy Statements

Investor FAQ

Investor & Media Contacts

SEC Filing Details

SEC Filing Details

Document Details

Form

Filing Date

Apr 14, 2017

Document Date

Apr 14, 2017

Filing Group

Other

Company

Frequency Therapeutics

Issuer

Frequency Therapeutics, Inc.

Filing Formats

View HTML